Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-980-9155
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
OptionableOptionable
Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions
What is Tonix Pharmaceuticals' stock symbol?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?
Tonix Pharmaceuticals shares reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Tonix Pharmaceuticals' earnings last quarter?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) released its quarterly earnings results on Friday, November, 9th. The company reported ($5.70) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($6.10) by $0.40. View Tonix Pharmaceuticals' Earnings History.
When is Tonix Pharmaceuticals' next earnings date?
What price target have analysts set for TNXP?
3 Wall Street analysts have issued 1 year price targets for Tonix Pharmaceuticals' stock. Their predictions range from $10.00 to $80.00. On average, they expect Tonix Pharmaceuticals' stock price to reach $45.00 in the next year. This suggests a possible upside of 2,207.7% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.
What is the consensus analysts' recommendation for Tonix Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tonix Pharmaceuticals.
Has Tonix Pharmaceuticals been receiving favorable news coverage?
Media coverage about TNXP stock has trended negative on Tuesday, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Tonix Pharmaceuticals' key competitors?
Some companies that are related to Tonix Pharmaceuticals include ERBA Diagnostics (ERBA), MYOS (MYOS), DelMar Pharmaceuticals (DMPI), International Stem Cell (ISCO), Cyclacel Pharmaceuticals (CYCC), MusclePharm (MSLP), NeuroVive Pharmaceutical (NEVPF), Vital Therapies (VTL), Aytu Bioscience (AYTU), Cellectar Biosciences (CLRB), Peak Pharmaceuticals (PKPH), Dare Bioscience (DARE), Regulus Therapeutics (RGLS), Diffusion Pharmaceuticals (DFFN) and Uluru (ULUR).
Who are Tonix Pharmaceuticals' key executives?
Tonix Pharmaceuticals' management team includes the folowing people:
- Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)
- Mr. Bradley Saenger, CFO & Treasurer (Age 45)
- Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)
- Mrs. Jessica Edgar Morris, Chief Operating Officer
- Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.
Who are Tonix Pharmaceuticals' major shareholders?
Tonix Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.13%), Geode Capital Management LLC (1.07%), CVI Holdings LLC (1.07%) and Citigroup Inc. (1.02%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.
Which institutional investors are selling Tonix Pharmaceuticals stock?
Which institutional investors are buying Tonix Pharmaceuticals stock?
TNXP stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, CVI Holdings LLC and Citigroup Inc.. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.
How do I buy shares of Tonix Pharmaceuticals?
Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tonix Pharmaceuticals' stock price today?
One share of TNXP stock can currently be purchased for approximately $1.95.
How big of a company is Tonix Pharmaceuticals?
Tonix Pharmaceuticals has a market capitalization of $2.98 million. The company earns $-21,120,000.00 in net income (profit) each year or ($29.00) on an earnings per share basis. Tonix Pharmaceuticals employs 14 workers across the globe.
What is Tonix Pharmaceuticals' official website?
How can I contact Tonix Pharmaceuticals?
Tonix Pharmaceuticals' mailing address is 509 MADISON AVE SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]
MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
